EXHIBIT 426

```
1
              UNITED STATES DISTRICT COURT
            FOR THE NORTHERN DISTRICT OF OHIO
 2
                    EASTERN DIVISION
                                     MDL No. 2804
 3
    IN RE: NATIONAL
    PRESCRIPTION OPIATE
    LITIGATION
                                    Case No.
                                     1:17-MD-2804
 5
                                    Hon. Dan A. Polster
    THIS DOCUMENT RELATES TO
    ALL CASES
 6
 7
 8
 9
10
                Friday, February 22, 2019
11
12
       HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
                 CONFIDENTIALITY REVIEW
13
14
15
16
17
            Videotaped Deposition of MATTHEW ROGOS,
     held at Marcus & Shapira LLP, One Oxford
     Centre, Suite 3500, Pittsburgh, Pennsylvania,
18
     commencing at 1:09 p.m., on the above date,
19
     before Michael E. Miller, Fellow of the
     Academy of Professional Reporters, Registered
     Diplomate Reporter, Certified Realtime
20
     Reporter and Notary Public.
21
22
23
24
                GOLKOW LITIGATION SERVICES
             877.370.3377 ph | fax 917.591.5672
25
                     deps@golkow.com
```

- the format, there might have been some edits
- that, as a group, the pharmacy key team, if
- we had questions amongst us, we would ask to
- 4 see how we wanted to, I guess, update the
- 5 policy, or if there were things in the VAWD
- 6 checklist that we needed to ensure that were
- 7 in the policies to get the certification, we
- 8 needed to put those in.
- 9 BY MR. BARTON:
- Q. Okay. So as of August of 2014,
- looking kind of at the effective date shown
- here for this policy on this document, on
- Exhibit 7, as of -- as of August 1st of 2014,
- do you recall having directed at HBC that
- there be any training of HBC employees on how
- one might identify an order from a pharmacy
- of controlled substances as suspicious?
- MR. KOBRIN: Object to form.
- A. What employees?
- 20 BY MR. BARTON:
- Q. Any. Anyone at the warehouse,
- I guess. Anyone under your supervision
- ultimately.
- A. I don't recall any specific
- training. There were employees that were in

- 1 place prior to my arrival at HBC that might
- 2 have gotten training.
- Q. Okay. Do you recall whether,
- 4 at HBC at the time we're talking about now,
- in 2014, was there like a learning management
- 6 system for employees to get all kinds of
- 7 training that they may need for their jobs?
- MR. KOBRIN: Object to form.
- 9 A. I can't recall.
- 10 BY MR. BARTON:
- 11 Q. Okay. You understand what I'm
- referring to, though, in terms of like an
- LMS, learning management system, for employee
- training? Is that something you have had
- familiarity with in your career?
- 16 A. It is.
- Q. And one of the things that an
- 18 LMS system can do if an employer sets it up
- this way is to have training for its
- employees, for example, on policies and
- procedures, correct?
- A. I would assume, yes.
- Q. Okay. But as you sit here, you
- don't recall whether that existed in that --
- whether that functionality existed in HBC at

- identify if a certain pharmacy within our
- 2 Giant Eagle system was ordering over -- or I
- guess overordering a certain prescription.
- I know that they did monitor
- 5 that and would send out monthly reports on
- 6 thresholds to us if any store was over the
- 7 threshold.
- Q. Okay. So there was a company
- 9 system, what you're referring to, that you
- understood was in place to be monitoring for
- orders that somehow were flagged by the
- system as potentially suspicious?
- 13 A. Correct.
- Q. Based on quantity or frequency
- or size or anything that the system might be
- 16 flagging?
- 17 A. I don't know what the specifics
- were on the flags, but yes.
- Q. Right. You didn't set up that
- system to kind of put in whatever parameters
- it had, correct?
- 22 A. No.
- Q. So that -- and my question was
- really just about what's -- what was in this
- written policy as of this point in time

```
1
      that -- none of that that you've just
 2.
     described, the companywide system or any
 3
     other criteria that employees might use for
 4
      identifying an order of suspicious -- an
 5
      order as suspicious, that's not -- that's not
 6
      explained in this document, correct?
 7
            Α.
                   No.
 8
            Ο.
                   Okay. What this document does
 9
     do is it addresses how HBC intended to
10
      respond if it identified or suspected an
11
      order as suspicious?
12
                   MR. KOBRIN: Object to form.
13
            Α.
                   That's correct.
14
                   MR. BARTON: Okay.
15
                    (HBC-Rogos Deposition Exhibit 8
16
            marked.)
17
     BY MR. BARTON:
18
                   I'm handing you Exhibit 8.
            Q.
19
     Exhibit 8 is a multiple-page document
20
      starting with page Bates number
21
     HBC MDL00132908; is that correct?
22
            Α.
                   Yes.
23
            0.
                   And the last page of this
24
     exhibit, Bates HBC MDL00132924; is that
25
      right?
```

- A. My understanding, yes, uh-huh.
- Q. There -- was there ever, during
- the time that you were director of warehouse
- 4 operations, was there ever any specific
- 5 training that you directed or conducted of
- 6 your employees on suspicious order
- 7 monitoring?
- 8 A. Not that I did.
- 9 Q. Okay. Did it ever occur? I
- mean, apart from whether you actually did the
- 11 training, did you -- do you know whether your
- employees ever got training on the specifics
- of suspicious order monitoring while you were
- director of warehouse operations?
- 15 A. No.
- Q. Okay. And I think you've
- testified there wasn't, to your recollection,
- or at least you're not able to say there was,
- an LMS training system where it would be
- documented somewhere that every employee was
- trained on these policies, correct?
- A. I'm not aware of that.
- Q. Okay. After -- after this
- 24 policy was revised to include the suspicious
- order criteria that counsel was just pointing